Overcoming Therapeutic Inertia in Type 2 Diabetes: Exploring Machine Learning-Based Scenario Simulation for Improving Short-Term Glycemic Control
Authors:
- Musacchio NicolettaMNMusacchio Nicoletta
- Rita ZilichRZRita Zilich
- Davide MasiDavide Masi
- Fabio BaccettiFBFabio Baccetti
- Besmir NreuBNBesmir Nreu
- Carlo Bruno GiordaCGCarlo Bruno Giorda
- Giacomo GuaitaGGGiacomo Guaita
- Lelio MorviducciLMLelio Morviducci
- Marco MuselliMMMarco Muselli
- Alessandro OzzelloAOAlessandro Ozzello
- Federico PisaniFPFederico Pisani
- Paola PonzaniPPPaola Ponzani
Open Access
- 14 February 2024
- journal article
- research article
- Published by MDPI AG in Machine Learning and Knowledge Extraction
- Vol. 6 (1) , 420-434
Abstract
Background: International guidelines for diabetes care emphasize the urgency of promptly achieving and sustaining adequate glycemic control to reduce the occurrence of micro/macrovascular complications in patients with type 2 diabetes mellitus (T2DM). However, data from the Italian Association of Medical Diabetologists (AMD) Annals reveal that only 47% of T2DM patients reach appropriate glycemic targets, with approximately 30% relying on insulin therapy, either solely or in combination. This artificial intelligence analysis seeks to assess the potential impact of timely insulin initiation in all eligible patients via a “what-if” scenario simulation, leveraging real-world data. Methods: This retrospective cohort study utilized the AMD Annals database, comprising 1,186,247 T2DM patients from 2005 to 2019. Employing the Logic Learning Machine (LLM), we simulated timely insulin use for all eligible patients, estimating its effect on glycemic control after 12 months within a cohort of 85,239 patients. Of these, 20,015 were employed for the machine learning phase and 65,224 for simulation. Results: Within the simulated scenario, the introduction of appropriate insulin therapy led to a noteworthy projected 17% increase in patients meeting the metabolic target after 12 months from therapy initiation within the cohort of 65,224 individuals. The LLM’s projection envisages 32,851 potential patients achieving the target (hemoglobin glycated < 7.5%) after 12 months, compared to 21,453 patients observed in real-world cases. The receiver operating characteristic (ROC) curve analysis for this model demonstrated modest performance, with an area under the curve (AUC) value of 70.4%. Conclusions: This study reaffirms the significance of combatting therapeutic inertia in managing T2DM patients. Early insulinization, when clinically appropriate, markedly enhances patients’ metabolic goals at the 12-month follow-up.Keywords
Funding Information
- Sanofi SpA
This publication has 33 references indexed in Scilit:
- On generating trustworthy counterfactual explanationsInformation Sciences, 2023
- The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes careDiabetes Research and Clinical Practice, 2023
- Control metabólico y pautas de tratamiento en pacientes con diabetes tipo 1 en Castilla-La Mancha, 10 años después. Estudio DIACAM1 2020Endocrinología, Diabetes y Nutrición, 2022
- Overcoming Therapeutic Inertia in Type 2 Diabetes Care—Timing, Context, and Appropriateness of Treatment IntensificationJAMA Network Open, 2021
- Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation studyJournal of Diabetes and its Complications, 2021
- A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USADiabetes Therapy, 2021
- Assessing the Effect of Clinical Inertia on Diabetes Outcomes: a Modeling ApproachJournal of General Internal Medicine, 2018
- Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysisDiabetes Research and Clinical Practice, 2018
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2014
- Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) studyDiabetes & Metabolism, 2003